Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Niclosamide Suppresses Cancer Cell Growth By Inducing Wnt Co-Receptor LRP6 Degradation and Inhibiting the Wnt/β-Catenin Pathway
- W. Lu, Cuihong Lin, M. J. Roberts, W. Waud, G. Piazza, Y. Li
- Biology, Medicine
- PloS one
- 16 December 2011
The Wnt/β-catenin signaling pathway is important for tumor initiation and progression. The low density lipoprotein receptor-related protein-6 (LRP6) is an essential Wnt co-receptor for Wnt/β-catenin… Expand
The mechanism of conversion of rat liver xanthine dehydrogenase from an NAD+-dependent form (type D) to an O2-dependent form (type O).
- W. Waud, K. Rajagopalan
- Chemistry, Medicine
- Archives of biochemistry and biophysics
- 1 February 1976
Abstract Rat liver xanthine dehydrogenase, type D, has been isolated directly from crude extracts as an antibody complex and its properties compared with those of two oxidase forms of the enzyme,… Expand
Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity
- J. Bertino, W. Waud, W. Parker, M. Lubin
- Biology, Medicine
- Cancer biology & therapy
- 1 April 2011
Many solid tumors and hematologic malignancies lack expression of the enzyme methylthioadenosine phosphorylase (MTAP), due either to deletion of the MTAP gene or to methylation of the MTAP promoter.… Expand
Preclinical antitumor activity of temozolomide in mice: efficacy against human brain tumor xenografts and synergism with 1,3-bis(2-chloroethyl)-1-nitrosourea.
- J. Plowman, W. Waud, A. Koutsoukos, L. Rubinstein, T. Moore, M. Grever
- Medicine
- Cancer research
- 15 July 1994
Temozolomide, a methylating agent with clinical activity against brain tumors, demonstrated excellent antitumor activity following p.o. administration to athymic mice bearing human brain tumor… Expand
Inborn errors of molybdenum metabolism: combined deficiencies of sulfite oxidase and xanthine dehydrogenase in a patient lacking the molybdenum cofactor.
- J. L. Johnson, W. Waud, K. Rajagopalan, M. Durán, F. Beemer, S. K. Wadman
- Chemistry, Medicine
- Proceedings of the National Academy of Sciences…
- 1 June 1980
A patient suffering from a combined deficiency of sulfite oxidase (sulfite dehydrogenase; sulfite:ferricytochrome c oxidoreductase, EC 1.8.2.1) and xanthine dehydrogenase (xanthine:NAD+… Expand
Purification and properties of the NAD+-dependent (type D) and O2-dependent (type O) forms of rat liver xanthine dehydrogenase.
- W. Waud, K. Rajagopalan
- Chemistry, Medicine
- Archives of biochemistry and biophysics
- 1 February 1976
Abstract The xanthine-oxidizing enzyme of rat liver has been purified as an NAD + -dependent dehydrogenase (type D) and as the O 2 -dependent oxidase (type O). The purified D and O variants are… Expand
Disposition and metabolism of aniline in Fischer 344 rats and C57BL/6 X C3H F1 mice.
- D. J. Mccarthy, W. Waud, R. Struck, D. Hill
- Chemistry, Medicine
- Cancer research
- 1985
We examined the metabolism and disposition of aniline, which induces spleen hemangiosarcomas in rats but no tumors in mice, in normal and predosed Fischer 344 rats, and C57BL/6 X C3H F1 mice… Expand
Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
- S. Kadhim, T. Bowlin, +6 authors G. Attardo
- Medicine
- Cancer research
- 1 November 1997
Beta-L-Dioxolane-cytidine (BCH-4556) is a novel anticancer nucleoside analogue with a stereochemically unnatural beta-L configuration. This compound was previously shown to have a potent antitumor… Expand
Response of human tumor xenografts in athymic nude mice to docetaxel (RP 56976, Taxotere®)
- D. Dykes, M. C. Bissery, S. Harrison, W. Waud
- Medicine
- Investigational New Drugs
- 2007
SummaryDocetaxel (Taxotere®, RP 56976, NSC 628503), a new taxoid, was evaluated for preclinical evidence of anticancer activity in athymic nude (NCr-nu) mice bearing established, subcutaneously… Expand
Preclinical antitumor activity of 4′-thio-β-d-arabinofuranosylcytosine (4′-thio-ara-C)
- W. Waud, K. S. Gilbert, Rodney V. Shepherd, J. Montgomery, J. A. Secrist
- Medicine
- Cancer Chemotherapy and Pharmacology
- 1 April 2003
Purpose4′-Thio-β-d-arabinofuranosylcytosine (4′-thio-ara-C), which has shown significant cytotoxicity against a panel of human tumor lines, was evaluated for antitumor activity against a spectrum of… Expand